<!doctype html><html lang=es-es dir=ltr data-wc-theme-default=system><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=X-UA-Compatible content="IE=edge"><meta name=generator content="Hugo Blox Builder 0.3.1"><meta name=author content="Maicel Monzon"><meta name=description content="Por Maicel Monzon
Introducci√≥n Los ensayos cl√≠nicos controlados, aleatorizados y enmascarados (ECAs) constituyen el marco metodol√≥gico m√°s robusto para evaluar la eficacia y seguridad de nuevas intervenciones terap√©uticas. Son considerados el &ldquo;est√°ndar de oro&rdquo; en investigaci√≥n cl√≠nica por agencias como ICH, EMA y FDA, ya que proporcionan el mayor control contra el sesgo y la mayor solidez en inferencia causal.
"><link rel=alternate hreflang=es-es href=https://bioestadisticaedu.com/post/atajos/><link rel=stylesheet href=/css/themes/sky.min.css><link href=/dist/wc.min.40d365a5c94bd94585e708f7c92e5782e00a8d8eefc348f5d2f21a80bb7783c8.css rel=stylesheet><script>window.hbb={defaultTheme:document.documentElement.dataset.wcThemeDefault,setDarkTheme:()=>{document.documentElement.classList.add("dark"),document.documentElement.style.colorScheme="dark"},setLightTheme:()=>{document.documentElement.classList.remove("dark"),document.documentElement.style.colorScheme="light"}},console.debug(`Default Hugo Blox Builder theme is ${window.hbb.defaultTheme}`),"wc-color-theme"in localStorage?localStorage.getItem("wc-color-theme")==="dark"?window.hbb.setDarkTheme():window.hbb.setLightTheme():(window.hbb.defaultTheme==="dark"?window.hbb.setDarkTheme():window.hbb.setLightTheme(),window.hbb.defaultTheme==="system"&&(window.matchMedia("(prefers-color-scheme: dark)").matches?window.hbb.setDarkTheme():window.hbb.setLightTheme()))</script><script>document.addEventListener("DOMContentLoaded",function(){let e=document.querySelectorAll("li input[type='checkbox'][disabled]");e.forEach(e=>{e.parentElement.parentElement.classList.add("task-list")});const t=document.querySelectorAll(".task-list li");t.forEach(e=>{let t=Array.from(e.childNodes).filter(e=>e.nodeType===3&&e.textContent.trim().length>1);if(t.length>0){const n=document.createElement("label");t[0].after(n),n.appendChild(e.querySelector("input[type='checkbox']")),n.appendChild(t[0])}})})</script><script async src="https://www.googletagmanager.com/gtag/js?id=G-VN0YPKYGX4"></script><script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}function trackOutboundLink(e,t){gtag("event","click",{event_category:"outbound",event_label:e,transport_type:"beacon",event_callback:function(){t!=="_blank"&&(document.location=e)}}),console.debug("Outbound link clicked: "+e)}function onClickCallback(e){if(e.target.tagName!=="A"||e.target.host===window.location.host)return;trackOutboundLink(e.target,e.target.getAttribute("target"))}gtag("js",new Date),gtag("config","G-VN0YPKYGX4",{}),gtag("set",{cookie_flags:"SameSite=None;Secure"}),document.addEventListener("click",onClickCallback,!1)</script><link rel=icon type=image/png href=/media/icon_hu_b45ae4411cf43192.png><link rel=apple-touch-icon type=image/png href=/media/icon_hu_1f7e870b5f23a0ce.png><link rel=canonical href=https://bioestadisticaedu.com/post/atajos/><meta property="twitter:card" content="summary_large_image"><meta property="twitter:site" content="@GetResearchDev"><meta property="twitter:creator" content="@GetResearchDev"><meta property="og:site_name" content="Bioestad√≠stica edu"><meta property="og:url" content="https://bioestadisticaedu.com/post/atajos/"><meta property="og:title" content="Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios | Bioestad√≠stica edu"><meta property="og:description" content="Por Maicel Monzon
Introducci√≥n
Los ensayos cl√≠nicos controlados, aleatorizados y enmascarados (ECAs) constituyen el marco metodol√≥gico m√°s robusto para evaluar la eficacia y seguridad de nuevas intervenciones terap√©uticas. Son considerados el &ldquo;est√°ndar de oro&rdquo; en investigaci√≥n cl√≠nica por agencias como ICH, EMA y FDA, ya que proporcionan el mayor control contra el sesgo y la mayor solidez en inferencia causal."><meta property="og:image" content="https://bioestadisticaedu.com/post/atajos/featured.png"><meta property="twitter:image" content="https://bioestadisticaedu.com/post/atajos/featured.png"><meta property="og:locale" content="es-es"><meta property="article:published_time" content="2025-08-07T00:00:00+00:00"><meta property="article:modified_time" content="2025-08-07T00:00:00+00:00"><title>Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios | Bioestad√≠stica edu</title><style>@font-face{font-family:inter var;font-style:normal;font-weight:100 900;font-display:swap;src:url(/dist/font/Inter.var.woff2)format(woff2)}</style><link type=text/css rel=stylesheet href=/dist/pagefind/pagefind-ui.be766eb419317a14ec769d216e9779bfe8f3737c80e780f4ba0dafb57a41a482.css integrity="sha256-vnZutBkxehTsdp0hbpd5v+jzc3yA54D0ug2vtXpBpII="><script src=/dist/pagefind/pagefind-ui.87693d7c6f2b3b347ce359d0ede762c033419f0a32b22ce508c335a81d841f1b.js integrity="sha256-h2k9fG8rOzR841nQ7ediwDNBnwoysizlCMM1qB2EHxs="></script><script>window.hbb.pagefind={baseUrl:"/"}</script><style>html.dark{--pagefind-ui-primary:#eeeeee;--pagefind-ui-text:#eeeeee;--pagefind-ui-background:#152028;--pagefind-ui-border:#152028;--pagefind-ui-tag:#152028}</style><script>window.addEventListener("DOMContentLoaded",e=>{new PagefindUI({element:"#search",showSubResults:!0,baseUrl:window.hbb.pagefind.baseUrl,bundlePath:window.hbb.pagefind.baseUrl+"pagefind/"})}),document.addEventListener("DOMContentLoaded",()=>{let e=document.getElementById("search"),t=document.getElementById("search_toggle");t&&t.addEventListener("click",()=>{if(e.classList.toggle("hidden"),e.querySelector("input").value="",e.querySelector("input").focus(),!e.classList.contains("hidden")){let t=document.querySelector(".pagefind-ui__search-clear");t&&!t.hasAttribute("listenerOnClick")&&(t.setAttribute("listenerOnClick","true"),t.addEventListener("click",()=>{e.classList.toggle("hidden")}))}})})</script><script defer src=/js/hugo-blox-es.min.e6965f872775fcb889e784756e346e58af6799db6f12e6c21a12272f7d3b1c1e.js integrity="sha256-5pZfhyd1/LiJ54R1bjRuWK9nmdtvEubCGhInL307HB4="></script></head><body class="dark:bg-hb-dark dark:text-white page-wrapper" id=top><div id=page-bg></div><div class="page-header sticky top-0 z-30"></div><div class="page-body my-10"><div class="mx-auto flex max-w-screen-xl"><aside class="hb-sidebar-container max-lg:[transform:translate3d(0,-100%,0)] lg:hidden xl:block"><div class="px-4 pt-4 lg:hidden"></div><div class="hb-scrollbar lg:h-[calc(100vh-var(--navbar-height))]"><ul class="flex flex-col gap-1 lg:hidden"><li class=open><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/>Blog BiestadisticaEdu
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/er-02/>El Frankenstein metodol√≥gico: desconexi√≥n inferencial entre fen√≥meno cl√≠nico y objetivos o hip√≥tesis</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/manifiesto-es/>Sobre este blog: estad√≠stica, salud y pensamiento cr√≠tico</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/er-01/>El Frankenstein metodol√≥gico: cuando la estad√≠stica responde otra pregunta</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/experimento-aula-ia/>Experimento en el aula: El d√≠a que el silicio me dio el Nobel</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/var-caso01/>VAR Cient√≠fico: El arte de mover la porter√≠a</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/experimento-aula-estudiantes/>Experimento en el aula: ¬øPueden los estudiantes enga√±ar a un bioestad√≠stico? Un concurso de fabricaci√≥n de datos</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/tendencias-bioestadistica/>Un An√°lisis Cr√≠tico del Curr√≠culo de Bioestad√≠stica Cubano Frente a las Tendencias Globales</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/museo-clasico/>El Museo de los Horrores Metodol√≥gicos: Sala de Arte Cl√°sico ‚Äì Cat√°logo Permanente</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/museo-2025/>El Museo de los Horrores Metodol√≥gicos A√±o 2025: La Era de la Alucinaci√≥n Artificial</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/siete-pecados-protocolos-clinicos/>Los siete pecados capitales del protocolo y del Plan de An√°lisis Estad√≠stico: confesiones de un regulador</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/imryd-redaccion-inversa/>¬øEscribir ciencia o reescribir la realidad?</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/inferencia-causal/>Inferencia Causal, Desvelando la L√≥gica Matem√°tica Detr√°s de Causa y Efecto</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/signifiacion/>Significaci√≥n Estad√≠stica, ¬øCiencia o Pirotecnia?</a></li><li class="flex flex-col open"><a class="hb-sidebar-custom-link
sidebar-active-item bg-primary-100 font-semibold text-primary-800 dark:bg-primary-300 dark:text-primary-900" href=/post/atajos/>Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios</a><ul class=hb-sidebar-mobile-toc><li><a href=#introducci%c3%b3n class=hb-docs-link>Introducci√≥n</a></li><li><a href=#tabla-1-t%c3%a9rminos-clave-definici%c3%b3n-origen-normativo-y-funci%c3%b3n-regulatoria class=hb-docs-link>Tabla 1. T√©rminos clave: definici√≥n, origen normativo y funci√≥n regulatoria</a></li><li><a href=#tabla-2-garant%c3%adas-anti-sesgo-en-ecas class=hb-docs-link>Tabla 2. Garant√≠as anti-sesgo en ECAs</a></li><li><a href=#tabla-3-dise%c3%b1os-alternativos-justificaci%c3%b3n-limitaciones-y-requisitos-regulatorios class=hb-docs-link>Tabla 3. Dise√±os alternativos: justificaci√≥n, limitaciones y requisitos regulatorios</a></li><li><a href=#riesgos-identificados class=hb-docs-link>Riesgos identificados:</a></li><li><a href=#a-para-la-industria class=hb-docs-link>A. Para la industria</a></li><li><a href=#b-para-las-agencias-reguladoras class=hb-docs-link>B. Para las agencias reguladoras</a></li></ul></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/ia/>Una Inmersi√≥n Intuitiva en la Arquitectura de los LLMs</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/generalizacion/>Generalizabilidad y Transportabilidad: Puente para llevar la ciencia al mundo real</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/eda/>An√°lisis Exploratorio de Datos: Desentra√±ando la Verdad de tus Datos</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/como-entrenar-y-validar-un-modelo-de-machine-learning/>C√≥mo Entrenar y Validar Modelos de Predicci√≥n Cl√≠nica: Gu√≠a Paso a Paso para Profesionales de la Salud</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/post/trampas-correlacion/>Las trampas de la correlaci√≥n disfrazada de causalidad</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/privacy/>Pol√≠tica de Privacidad y Confidencialidad Profesional</a></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/collaborations/>Colaboraciones Profesionales</a></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/>Projects
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/2025-12-12-pinocho/>Herramienta interactiva: Detector Forense de Datos Falsos</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/simed-simulacion-medica-en-linea/>SIMED: Simulaci√≥n M√©dica en L√≠nea para el Aprendizaje del Proceso de Atenci√≥n</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/plate-to-policy-real-time-ai-driven-insights-for-smarter-food-fortification/>MacroScope AI: Real-Time Nutrition Insights for Smarter Food Systems</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/covidcencecapk/>CovidCencecAPK</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/subscribe/>Suscr√≠bete a Nuestro Contenido</a></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/>Teaching
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/introducci-n-a-los-dise-os-explicativos-experimentales/>Conferencia de Introducci√≥n a los dise√±os explicativos experimentales</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/conferencia-introducci-n-al-an-lisis-estad-stico-en-ensayos-cl-nicos/>Conferencia de Introducci√≥n al an√°lisis estad√≠stico en ensayos cl√≠nicos</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/r/>Curso de An√°lisis de datos en fortificaci√≥n de alimentos a gran escala con R. Una Introducci√≥n Pr√°ctica</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/slides/>Presentaciones
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/slides/ec/>Dise√±os explicativos experimentales</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/event/>Recent & Upcoming Talks
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/event/example/>üëã Curso de An√°lisis de Datos en Fortificaci√≥n de Alimentos con R. Una Introducci√≥n Pr√°ctica</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href><span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href>Maicel Monzon</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href>Maicel Monzon</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/projects/>Projects</a></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/experience/>Experience</a></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/>Publications
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/journal-article/>Estado en la investigaci√≥n sobre modelos de predicci√≥n de la severidad en confirmados de la Covid-19.</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/preprint/>Identificaci√≥n de pacientes de bajo riesgo de severidad en confirmados de la COVID-19. Cuba. A√±os 2020-2021</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/2025-09-23-modelo-sir-para-epidemias-persistencia-en-el-tiempo-y-nuevos-retos-en-la-era-de-la-inform-tica-y-las-pandemias/>Modelo SIR para epidemias: Persistencia en el tiempo y nuevos retos en la era de la Inform√°tica y las pandemias.</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/2025-09-23-plagio-en-art-culos-de-investigaci-n-en-revistas-biom-dicas-cubanas-2016/>Plagio en art√≠culos de investigaci√≥n en revistas biom√©dicas cubanas. 2016</a></li></ul></div></li></ul><div class="max-xl:hidden h-0 w-64 shrink-0"></div></div></aside><nav class="hb-toc order-last hidden w-64 shrink-0 xl:block print:hidden px-4" aria-label="table of contents"><div class="hb-scrollbar text-sm [hyphens:auto] sticky top-16 overflow-y-auto pr-4 pt-6 max-h-[calc(100vh-var(--navbar-height)-env(safe-area-inset-bottom))] -mr-4 rtl:-ml-4"><p class="mb-4 font-semibold tracking-tight">En esta p√°gina</p><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#introducci%c3%b3n>Introducci√≥n</a></li><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#tabla-1-t%c3%a9rminos-clave-definici%c3%b3n-origen-normativo-y-funci%c3%b3n-regulatoria>Tabla 1. T√©rminos clave: definici√≥n, origen normativo y funci√≥n regulatoria</a></li></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#tabla-2-garant%c3%adas-anti-sesgo-en-ecas>Tabla 2. Garant√≠as anti-sesgo en ECAs</a></li></ul><ul></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#tabla-3-dise%c3%b1os-alternativos-justificaci%c3%b3n-limitaciones-y-requisitos-regulatorios>Tabla 3. Dise√±os alternativos: justificaci√≥n, limitaciones y requisitos regulatorios</a></li></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#riesgos-identificados>Riesgos identificados:</a></li></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#a-para-la-industria>A. Para la industria</a></li><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#b-para-las-agencias-reguladoras>B. Para las agencias reguladoras</a></li></ul><ul></ul><ul></ul>
    
    
  </div></nav><article class="w-full break-words flex min-h-[calc(100vh-var(--navbar-height))] min-w-0 justify-center pb-8 pr-[calc(env(safe-area-inset-right)-1.5rem)]"><main class="w-full min-w-0 max-w-6xl px-6 pt-4 md:px-12"><div class=mb-4><div class="mt-1.5 flex items-center gap-1 overflow-hidden text-sm text-gray-500 dark:text-gray-400"><div class="whitespace-nowrap transition-colors min-w-[24px] overflow-hidden text-ellipsis hover:text-gray-900 dark:hover:text-gray-100"><a href=https://bioestadisticaedu.com/post/>Blog BiestadisticaEdu</a></div><svg class="w-3.5 shrink-0" viewBox="0 0 24 24"><path fill="none" stroke="currentcolor" stroke-linecap="round" stroke-linejoin="round" stroke-width="1.5" d="m8.25 4.5 7.5 7.5-7.5 7.5"/></svg><div class="whitespace-nowrap font-medium text-gray-700 dark:text-gray-100">Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios</div></div></div><h1 class="mt-2 text-4xl font-bold tracking-tight text-slate-900 dark:text-slate-100">Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios</h1><div class="mt-4 mb-16"><div class="text-gray-500 dark:text-gray-300 text-sm flex items-center flex-wrap gap-y-2"><span class=mr-1>ago. 7, 2025</span>
<span class=mx-1>¬∑</span>
<span class=mx-1>5 min de lectura</span></div><div class=mt-3></div></div><div class="article-header article-container featured-image-wrapper mt-4 mb-16" style=max-width:720px;max-height:720px><div style=position:relative><img src=/post/atajos/featured_hu_8cab0513d133f2b1.webp width=720 height=720 alt class=featured-image></div></div><div class="prose prose-slate lg:prose-xl dark:prose-invert"><p><em>Por Maicel Monzon</em></p><h2 id=introducci√≥n>Introducci√≥n</h2><p>Los ensayos cl√≠nicos controlados, aleatorizados y enmascarados (ECAs) constituyen el marco metodol√≥gico m√°s robusto para evaluar la <strong>eficacia y seguridad</strong> de nuevas intervenciones terap√©uticas. Son considerados el &ldquo;est√°ndar de oro&rdquo; en investigaci√≥n cl√≠nica por agencias como <strong>ICH, EMA y FDA</strong>, ya que proporcionan el mayor control contra el sesgo y la mayor solidez en inferencia causal.</p><p>En este marco, los <strong>ensayos confirmatorios</strong> son aquellos dise√±ados expl√≠citamente para confirmar hip√≥tesis cl√≠nicas relevantes, con base en an√°lisis predefinidos y control adecuado de errores. Cuando estos estudios sustentan una solicitud de comercializaci√≥n, adquieren la condici√≥n de <strong>ensayos pivotal</strong> (terminolog√≠a empleada por FDA y EMA).</p><p>En principio, se recomienda la presentaci√≥n de <strong>dos ensayos confirmatorios independientes</strong>. Sin embargo, <strong>tanto EMA como FDA</strong> contemplan aprobaciones basadas en <strong>un √∫nico ensayo pivotal</strong>, siempre que est√© respaldado por <strong>evidencia complementaria rigurosa</strong>. La <strong>FDA</strong>, mediante el concepto de <strong>evidencia confirmatoria</strong> (FDA 2023), formaliza esta v√≠a alternativa. La <strong>EMA</strong>, aunque no utiliza esa denominaci√≥n, acepta enfoques equivalentes (meta-an√°lisis, controles hist√≥ricos validados, an√°lisis de consistencia interna).</p><h2 id=tabla-1-t√©rminos-clave-definici√≥n-origen-normativo-y-funci√≥n-regulatoria>Tabla 1. T√©rminos clave: definici√≥n, origen normativo y funci√≥n regulatoria</h2><table><thead><tr><th><strong>T√©rmino</strong></th><th><strong>Fuente regulatoria</strong></th><th><strong>Definici√≥n t√©cnica</strong></th><th><strong>Funci√≥n regulatoria</strong></th></tr></thead><tbody><tr><td><strong>Ensayo cl√≠nico confirmatorio</strong></td><td>ICH E9</td><td>Estudio con hip√≥tesis expl√≠cita, an√°lisis planificado y dise√±o robusto para inferencia causal.</td><td>Fuente principal de evidencia en autorizaciones de comercializaci√≥n.</td></tr><tr><td><strong>Ensayo pivotal</strong></td><td>FDA, EMA</td><td>Estudio esencial para demostrar eficacia y seguridad en el expediente regulatorio.</td><td>Sustento central del dossier cl√≠nico.</td></tr><tr><td><strong>Evidencia confirmatoria</strong></td><td>FDA (2023)</td><td>Datos adicionales (cl√≠nicos/no cl√≠nicos) que refuerzan un ensayo pivotal √∫nico.</td><td>Permite cumplir el est√°ndar de &ldquo;evidencia sustancial&rdquo; con un solo ECA.</td></tr><tr><td><strong>Evidencia sustancial</strong></td><td>FDA (21 CFR 314.126)</td><td>Est√°ndar legal que puede cumplirse mediante 2 ECAs o, cuando est√© justificado, 1 ECA + confirmaci√≥n.</td><td>Requisito para la aprobaci√≥n de nuevos medicamentos en EE.UU.</td></tr><tr><td><strong>Evidencia complementaria</strong></td><td>ICH E9; EMA, FDA</td><td>Estudios no pivotal que aportan consistencia (ej. subgrupos, dosis, seguridad, datos externos).</td><td>Reforzar la plausibilidad de los hallazgos principales.</td></tr></tbody></table><hr><h1 id=estructura-metodol√≥gica-de-los-ecas-y-su-anclaje-normativo>Estructura metodol√≥gica de los ECAs y su anclaje normativo</h1><p>Los ECAs incorporan tres garant√≠as fundamentales: <strong>aleatorizaci√≥n</strong>, <strong>grupo control</strong> y <strong>cegamiento</strong>. Estos componentes son esenciales para maximizar la validez interna y minimizar fuentes de sesgo sistem√°tico.</p><h2 id=tabla-2-garant√≠as-anti-sesgo-en-ecas>Tabla 2. Garant√≠as anti-sesgo en ECAs</h2><table><thead><tr><th><strong>Componente metodol√≥gico</strong></th><th><strong>Funci√≥n espec√≠fica</strong></th><th><strong>C√≥mo reduce el sesgo</strong></th><th><strong>Referencia normativa ICH</strong></th></tr></thead><tbody><tr><td><strong>Aleatorizaci√≥n</strong></td><td>Asignaci√≥n no predecible de tratamientos</td><td>Mitiga el sesgo de selecci√≥n; equilibra factores conocidos/desconocidos</td><td>ICH E9 Secci√≥n 2.2.3</td></tr><tr><td><strong>Grupo control</strong></td><td>Comparaci√≥n con placebo o tratamiento est√°ndar</td><td>Permite contrafactual v√°lido e inferencia causal robusta</td><td>ICH E10; ICH E8(R1)</td></tr><tr><td><strong>Cegamiento (blinding)</strong></td><td>Ocultamiento de asignaci√≥n a participantes e investigadores</td><td>Previene sesgo de evaluaci√≥n, expectativa y cointervenci√≥n</td><td>ICH E9 Secci√≥n 2.2.4</td></tr></tbody></table><hr><h1 id=contextos-que-permiten-prescindir-de-ecas>Contextos que permiten prescindir de ECAs</h1><p>La omisi√≥n de ECAs solo es aceptable en contextos claramente delimitados por justificaciones √©ticas, cient√≠ficas o log√≠sticas:</p><ol><li><strong>Enfermedades raras o ultrarraras</strong>, con poblaciones muy limitadas.</li><li><strong>Situaciones de emergencia sanitaria</strong>, con necesidades cl√≠nicas urgentes.</li><li>Cuando la <strong>aleatorizaci√≥n o el cegamiento son √©ticamente problem√°ticos</strong>.</li><li>Cuando existen <strong>datos hist√≥ricos o reales bien estructurados y validados</strong>.</li></ol><p>La aceptaci√≥n de estos dise√±os como base regulatoria <strong>requiere validaci√≥n metodol√≥gica espec√≠fica y evaluaci√≥n caso por caso</strong>, seg√∫n gu√≠as EMA y FDA.</p><hr><h1 id=dise√±os-alternativos-m√°s-empleados-y-criterios-de-validaci√≥n>Dise√±os alternativos m√°s empleados y criterios de validaci√≥n</h1><h2 id=tabla-3-dise√±os-alternativos-justificaci√≥n-limitaciones-y-requisitos-regulatorios>Tabla 3. Dise√±os alternativos: justificaci√≥n, limitaciones y requisitos regulatorios</h2><table><thead><tr><th><strong>Dise√±o alternativo</strong></th><th><strong>Justificaci√≥n de uso</strong></th><th><strong>Limitaciones cr√≠ticas</strong></th><th><strong>Requisitos de validaci√≥n</strong></th></tr></thead><tbody><tr><td><strong>Single-Arm Trials (SAT)</strong></td><td>Enfermedades raras; oncolog√≠a sin comparador disponible</td><td>Ausencia de grupo control; alta vulnerabilidad a sesgo de selecci√≥n</td><td>Control externo robusto; endpoints validados; an√°lisis de consistencia</td></tr><tr><td><strong>Controles externos/sint√©ticos</strong></td><td>Cohortes hist√≥ricas o datos de mundo real</td><td>Riesgo de confusi√≥n residual y sesgo de canalizaci√≥n</td><td>Propensity score matching; alineaci√≥n temporal; CHMP/4366/2020 (EMA)</td></tr><tr><td><strong>Dise√±os adaptativos</strong></td><td>Eficiencia en reclutamiento; ajustes preplanificados</td><td>Riesgo de error tipo I si no se prespecifican adecuadamente</td><td>Control de multiplicidad; simulaci√≥n previa; ICH E9(R1)</td></tr><tr><td><strong>Real-World Evidence (RWE)</strong></td><td>Acceso a datos de rutina cl√≠nica; seguimiento largo; baja carga √©tica</td><td>Falta de aleatorizaci√≥n; sesgo de confusi√≥n no medido</td><td>PROACE principles (FDA 2023); data provenance; calidad del DMR; plan de an√°lisis riguroso</td></tr></tbody></table><hr><h1 id=riesgos-del-uso-estrat√©gico-de-dise√±os-no-confirmatorios>Riesgos del uso estrat√©gico de dise√±os no confirmatorios</h1><p>Aunque v√°lidos en contextos excepcionales, el uso frecuente y estrat√©gico de estos dise√±os plantea <strong>serios desaf√≠os regulatorios</strong>, especialmente si se recurre a ellos como v√≠a para <strong>prescindir de ECAs sin justificaci√≥n metodol√≥gica s√≥lida</strong>.</p><h2 id=riesgos-identificados>Riesgos identificados:</h2><ul><li>Aprobaciones basadas en <strong>evidencia d√©bil o no reproducible</strong>.</li><li>Incremento del <strong>sesgo sistem√°tico</strong> en resultados de eficacia.</li><li>Exposici√≥n de pacientes a intervenciones <strong>no validadas rigurosamente</strong>.</li><li><strong>Deslegitimaci√≥n del proceso regulatorio</strong> ante la comunidad cient√≠fica y la sociedad.</li></ul><hr><h1 id=recomendaciones-regulatorias>Recomendaciones regulatorias</h1><h2 id=a-para-la-industria>A. Para la industria</h2><ul><li>Presentar <strong>justificaci√≥n exhaustiva</strong> cuando no se utilicen ECAs.</li><li>Cumplir con requisitos metodol√≥gicos espec√≠ficos seg√∫n tipo de dise√±o alternativo.</li><li>Incluir an√°lisis de sensibilidad, consistencia y control de sesgo.</li></ul><h2 id=b-para-las-agencias-reguladoras>B. Para las agencias reguladoras</h2><ul><li><strong>Reforzar gu√≠as espec√≠ficas</strong> (EMA, FDA) que regulen el uso de dise√±os alternativos.</li><li>Exigir <strong>registro p√∫blico</strong>, transparencia y acceso a protocolos completos.</li><li>Fortalecer <strong>capacidades internas</strong> en estad√≠stica avanzada y dise√±o de estudios no aleatorizados.</li><li>Establecer <strong>comit√©s independientes</strong> de evaluaci√≥n para salvaguardas √©ticas y cient√≠ficas.</li></ul><hr><h1 id=conclusi√≥n>Conclusi√≥n</h1><p>Los dise√±os alternativos no deben entenderse como sustitutos gen√©ricos del ECA, sino como herramientas <strong>v√°lidas solo bajo condiciones estrictamente justificadas y validadas</strong>. El regulador tiene la responsabilidad cient√≠fica y √©tica de exigir evidencia que no solo sea suficiente, sino tambi√©n s√≥lida, reproducible y libre de sesgos. La precisi√≥n metodol√≥gica y la claridad terminol√≥gica no son un lujo en este proceso: <strong>son el principio rector que protege la salud p√∫blica frente a la ambig√ºedad cient√≠fica</strong>.</p><hr><hr><h1 id=bibliograf√≠a>Bibliograf√≠a</h1><ol><li>FDA. <em>Demonstrating Substantial Evidence of Effectiveness with One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence</em>. Draft Guidance. 2023.</li><li>EMA. <em>Reflection Paper on Single‚ÄëArm Trials as Pivotal Evidence</em>. EMA/CHMP/161300/2023.</li><li>FDA. <em>Real-World Evidence Framework</em>. 2023 Update.</li><li>EMA. <em>Use of Real‚ÄëWorld Evidence in Regulatory Decision-Making</em>. EMA/INS/GCP/455222/2024.</li><li>ICH. <em>E9: Statistical Principles for Clinical Trials</em>. 1998.</li><li>ICH. <em>E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials</em>. 2020.</li><li>EMA. <em>Guideline on Adjustment for Baseline Covariates in Clinical Trials</em>. CHMP/EWP/2863/99.</li><li>FDA. <em>Real-World Evidence Program Annual Report 2025 (PUB-245)</em>.</li><li>Temple R, Ellenberg SS. <em>Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments</em>. <em>Ann Intern Med</em>. 2000;133(6):455‚Äì463.</li></ol></div><time class="mt-12 mb-8 block text-xs text-gray-500 ltr:text-right rtl:text-left dark:text-gray-400" datetime=2025-08-07T00:00:00.000Z><span>√öltima actualizaci√≥n el</span>
ago. 7, 2025</time><div class="container mx-auto prose prose-slate lg:prose-xl dark:prose-invert mt-5"><div class="max-w-prose print:hidden"><div class="flex justify-center"><a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/evaluacion-regulatoria/>Evaluaci√≥n Regulatoria</a>
<a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/ensayos-clinicos/>Ensayos Cl√≠nicos</a>
<a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/atajos-disenos-ensayos-clinicos-y-riesgos-ich/>Atajos Dise√±os Ensayos Cl√≠nicos Y Riesgos ICH</a>
<a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/guia-validacion-regulatoria-para-evaluadores/>Gu√≠a Validaci√≥n Regulatoria Para Evaluadores</a></div><section class="flex flex-row flex-wrap justify-center pt-4 text-xl"><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fbioestadisticaedu.com%2Fpost%2Fatajos%2F&amp;text=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios" title=X aria-label=X id=share-link-x><svg style="height:1em" viewBox="0 0 512 512"><path fill="currentcolor" d="M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="https://www.facebook.com/sharer.php?u=https%3A%2F%2Fbioestadisticaedu.com%2Fpost%2Fatajos%2F&amp;t=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios" title=Facebook aria-label=Facebook id=share-link-facebook><svg style="height:1em" viewBox="0 0 24 24"><path fill="currentcolor" d="M22 12c0-5.52-4.48-10-10-10S2 6.48 2 12c0 4.84 3.44 8.87 8 9.8V15H8v-3h2V9.5C10 7.57 11.57 6 13.5 6H16v3h-2c-.55.0-1 .45-1 1v2h3v3h-3v6.95c5.05-.5 9-4.76 9-9.95z"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="mailto:?subject=Dise%C3%B1os%20Alternativos%20a%20Ensayos%20Cl%C3%ADnicos%20Controlados%20Aleatorizados%3A%20Contextos%20de%20Aplicaci%C3%B3n%20y%20Riesgos%20Regulatorios&amp;body=https%3A%2F%2Fbioestadisticaedu.com%2Fpost%2Fatajos%2F" title=Email aria-label=Email id=share-link-email><svg style="height:1em" viewBox="0 0 24 24"><path fill="none" stroke="currentcolor" stroke-linecap="round" stroke-width="1.5" d="M16.5 12a4.5 4.5.0 11-9 0 4.5 4.5.0 019 0zm0 0c0 1.657 1.007 3 2.25 3S21 13.657 21 12a9 9 0 10-2.636 6.364M16.5 12V8.25"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fbioestadisticaedu.com%2Fpost%2Fatajos%2F&amp;title=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios" title=LinkedIn aria-label=LinkedIn id=share-link-linkedin><svg style="height:1em" height="1em" viewBox="0 0 448 512"><path fill="currentcolor" d="M416 32H31.9C14.3 32 0 46.5.0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6.0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3.0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2.0 38.5 17.3 38.5 38.5.0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6.0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2.0 79.7 44.3 79.7 101.9V416z"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="whatsapp://send?text=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios%20https%3A%2F%2Fbioestadisticaedu.com%2Fpost%2Fatajos%2F" title=WhatsApp aria-label=WhatsApp id=share-link-whatsapp><svg style="height:1em" viewBox="0 0 256 256" fill="currentcolor"><path d="m187.58 144.84-32-16a8 8 0 00-8 .5l-14.69 9.8a40.55 40.55.0 01-16-16l9.8-14.69a8 8 0 00.5-8l-16-32A8 8 0 00104 64a40 40 0 00-40 40 88.1 88.1.0 0088 88 40 40 0 0040-40 8 8 0 00-4.42-7.16zM152 176a72.08 72.08.0 01-72-72 24 24 0 0119.29-23.54l11.48 23L101 118a8 8 0 00-.73 7.51 56.47 56.47.0 0030.15 30.15A8 8 0 00138 155l14.61-9.74 23 11.48A24 24 0 01152 176zM128 24A104 104 0 0036.18 176.88l-11.35 34.05a16 16 0 0020.24 20.24l34.05-11.35A104 104 0 10128 24zm0 192a87.87 87.87.0 01-44.06-11.81 8 8 0 00-6.54-.67L40 216l12.47-37.4a8 8 0 00-.66-6.54A88 88 0 11128 216z"/></svg></a></section><div class="flex pt-12 pb-4"><img class="mr-4 h-24 w-24 rounded-full" width=96 height=96 alt="Maicel Monzon" src=/authors/admin/avatar_hu_3534db34d293129b.jpg loading=lazy><div class=place-self-center><div class="text-[0.6rem] uppercase leading-3 text-neutral-500 dark:text-neutral-400">Autores</div><div class="font-semibold leading-6 text-neutral-800 dark:text-neutral-300"><a href=https://bioestadisticaedu.com/ class=no-underline>Maicel Monzon</a></div><div class="text-sm font-bold text-neutral-700 dark:text-neutral-300">M√©dico, Bioestad√≠stico y Cient√≠fico de datos</div><div class="text-2xl sm:text-lg pt-1"><div class="flex flex-wrap text-neutral-500 dark:text-neutral-300"><a class="pr-2 transition-transform hover:scale-125 hover:text-primary-700 dark:hover:text-primary-400" style=will-change:transform href=mailto:maicel.monzon@gmail.com aria-label=At-Symbol><svg style="height:1em" viewBox="0 0 24 24"><path fill="none" stroke="currentcolor" stroke-linecap="round" stroke-width="1.5" d="M16.5 12a4.5 4.5.0 11-9 0 4.5 4.5.0 019 0zm0 0c0 1.657 1.007 3 2.25 3S21 13.657 21 12a9 9 0 10-2.636 6.364M16.5 12V8.25"/></svg></a>
<a class="pr-2 transition-transform hover:scale-125 hover:text-primary-700 dark:hover:text-primary-400" style=will-change:transform href=https://x.com/maicel1978 target=_blank rel=noopener rel="me noopener noreferrer" aria-label=Brands/X><svg style="height:1em" viewBox="0 0 512 512"><path fill="currentcolor" d="M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z"/></svg></a>
<a class="pr-2 transition-transform hover:scale-125 hover:text-primary-700 dark:hover:text-primary-400" style=will-change:transform href=https://www.instagram.com/maicel1978/ target=_blank rel=noopener rel="me noopener noreferrer" aria-label=Brands/Instagram><svg style="height:1em" viewBox="0 0 15 15"><path fill="currentcolor" fill-rule="evenodd" d="M12.91 12.909c.326-.327.582-.72.749-1.151.16-.414.27-.886.302-1.578.032-.693.04-.915.04-2.68.0-1.765-.008-1.987-.04-2.68-.032-.692-.142-1.164-.302-1.578a3.185 3.185.0 00-.75-1.151 3.187 3.187.0 00-1.151-.75c-.414-.16-.886-.27-1.578-.302C9.487 1.007 9.265 1 7.5 1c-1.765.0-1.987.007-2.68.04-.692.03-1.164.14-1.578.301a3.2 3.2.0 00-1.151.75 3.2 3.2.0 00-.75 1.151c-.16.414-.27.886-.302 1.578C1.007 5.513 1 5.735 1 7.5s.007 1.987.04 2.68c.03.692.14 1.164.301 1.578.164.434.42.826.75 1.151.325.33.718.586 1.151.75.414.16.886.27 1.578.302.693.031.915.039 2.68.039s1.987-.008 2.68-.04c.692-.03 1.164-.14 1.578-.301a3.323 3.323.0 001.151-.75zM2 6.735v1.53c-.002.821-.002 1.034.02 1.5.026.586.058 1.016.156 1.34.094.312.199.63.543 1.012.344.383.675.556 1.097.684.423.127.954.154 1.415.175.522.024.73.024 1.826.024H8.24c.842.001 1.054.002 1.526-.02.585-.027 1.015-.059 1.34-.156.311-.094.629-.2 1.011-.543.383-.344.556-.676.684-1.098.127-.422.155-.953.176-1.414C13 9.247 13 9.04 13 7.947v-.89c0-1.096.0-1.303-.023-1.826-.021-.461-.049-.992-.176-1.414-.127-.423-.3-.754-.684-1.098-.383-.344-.7-.449-1.011-.543-.325-.097-.755-.13-1.34-.156A27.29 27.29.0 008.24 2H7.057c-1.096.0-1.304.0-1.826.023-.461.021-.992.049-1.415.176-.422.128-.753.301-1.097.684s-.45.7-.543 1.012c-.098.324-.13.754-.156 1.34-.022.466-.022.679-.02 1.5zM7.5 5.25a2.25 2.25.0 100 4.5 2.25 2.25.0 000-4.5zM4.25 7.5a3.25 3.25.0 116.5.0 3.25 3.25.0 01-6.5.0zm6.72-2.72a.75.75.0 100-1.5.75.75.0 000 1.5z" clip-rule="evenodd"/></svg></a>
<a class="pr-2 transition-transform hover:scale-125 hover:text-primary-700 dark:hover:text-primary-400" style=will-change:transform href=https://github.com/maicel1978 target=_blank rel=noopener rel="me noopener noreferrer" aria-label=Brands/Github><svg style="height:1em" fill="currentcolor" viewBox="3 3 18 18"><path d="M12 3C7.0275 3 3 7.12937 3 12.2276c0 4.0833 2.57625 7.5321 6.15374 8.7548C9.60374 21.0631 9.77249 20.7863 9.77249 20.5441 9.77249 20.3249 9.76125 19.5982 9.76125 18.8254 7.5 19.2522 6.915 18.2602 6.735 17.7412 6.63375 17.4759 6.19499 16.6569 5.8125 16.4378 5.4975 16.2647 5.0475 15.838 5.80124 15.8264 6.51 15.8149 7.01625 16.4954 7.18499 16.7723 7.99499 18.1679 9.28875 17.7758 9.80625 17.5335 9.885 16.9337 10.1212 16.53 10.38 16.2993 8.3775 16.0687 6.285 15.2728 6.285 11.7432c0-1.0035.34875-1.834.92249-2.47994C7.1175 9.03257 6.8025 8.08674 7.2975 6.81794c0 0 .753749999999999-.24223 2.47499.94583.72001-.20762 1.48501-.31143 2.25001-.31143C12.7875 7.45234 13.5525 7.55615 14.2725 7.76377c1.7212-1.19959 2.475-.94583 2.475-.94583C17.2424 8.08674 16.9275 9.03257 16.8375 9.26326 17.4113 9.9092 17.76 10.7281 17.76 11.7432c0 3.5411-2.1037 4.3255-4.1063 4.5561C13.98 16.5877 14.2613 17.1414 14.2613 18.0065 14.2613 19.2407 14.25 20.2326 14.25 20.5441 14.25 20.7863 14.4188 21.0746 14.8688 20.9824 16.6554 20.364 18.2079 19.1866 19.3078 17.6162c1.0999-1.5705 1.6917-3.4551 1.6922-5.3886C21 7.12937 16.9725 3 12 3z"/></svg></a>
<a class="pr-2 transition-transform hover:scale-125 hover:text-primary-700 dark:hover:text-primary-400" style=will-change:transform href=https://www.linkedin.com/in/maicel-monzon/ target=_blank rel=noopener rel="me noopener noreferrer" aria-label=Brands/Linkedin><svg style="height:1em" height="1em" viewBox="0 0 448 512"><path fill="currentcolor" d="M416 32H31.9C14.3 32 0 46.5.0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6.0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3.0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2.0 38.5 17.3 38.5 38.5.0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6.0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2.0 79.7 44.3 79.7 101.9V416z"/></svg></a>
<a class="pr-2 transition-transform hover:scale-125 hover:text-primary-700 dark:hover:text-primary-400" style=will-change:transform href="https://scholar.google.com/citations?hl=es&amp;user=eWid-9gAAAAJ" target=_blank rel=noopener rel="me noopener noreferrer" aria-label=Academicons/Google-Scholar><svg style="height:1em" viewBox="0 0 512 512"><path fill="currentcolor" d="M343.759 106.662V79.43L363.524 64h-213.89L20.476 176.274h85.656a82.339 82.339.0 00-.219 6.225c0 20.845 7.22 38.087 21.672 51.861 14.453 13.797 32.252 20.648 53.327 20.648 4.923.0 9.75-.368 14.438-1.024-2.907 6.5-4.374 12.523-4.374 18.142.0 9.875 4.499 20.43 13.467 31.642-39.234 2.67-68.061 9.732-86.437 21.163-10.531 6.5-19 14.704-25.39 24.531-6.391 9.9-9.578 20.515-9.578 31.962.0 9.648 2.062 18.336 6.219 26.062 4.156 7.726 9.578 14.07 16.312 18.984 6.718 4.968 14.469 9.101 23.219 12.469 8.734 3.344 17.406 5.718 26.061 7.062A167.052 167.052.0 00180.555 448c13.469.0 26.953-1.734 40.547-5.187 13.562-3.485 26.28-8.642 38.171-15.493 11.86-6.805 21.515-16.086 28.922-27.718 7.39-11.68 11.094-24.805 11.094-39.336.0-11.016-2.25-21.039-6.75-30.14-4.468-9.073-9.938-16.542-16.452-22.345-6.501-5.813-13-11.155-19.516-15.968-6.5-4.845-12-9.75-16.468-14.813-4.485-5.046-6.735-10.054-6.735-14.984.0-4.921 1.734-9.672 5.216-14.265 3.455-4.61 7.674-9.048 12.61-13.306 4.937-4.25 9.875-8.968 14.796-14.133 4.922-5.147 9.141-11.827 12.61-20.008 3.485-8.18 5.203-17.445 5.203-27.757.0-13.453-2.547-24.46-7.547-33.314-.594-1.022-1.218-1.803-1.875-3.022l56.907-46.672v17.119c-7.393.93-6.624 5.345-6.624 10.635V245.96c0 5.958 4.875 10.834 10.834 10.834h3.989c5.958.0 10.833-4.875 10.833-10.834V117.293c0-5.277.778-9.688-6.561-10.63zm-107.36 222.48c1.14.75 3.704 2.78 7.718 6.038 4.05 3.243 6.797 5.695 8.266 7.414a443.553 443.553.0 016.376 7.547c2.813 3.375 4.718 6.304 5.718 8.734 1 2.477 2.016 5.461 3.047 8.946a38.27 38.27.0 011.485 10.562c0 17.048-6.564 29.68-19.656 37.859-13.125 8.18-28.767 12.274-46.938 12.274-9.187.0-18.203-1.093-27.063-3.196-8.843-2.116-17.311-5.336-25.39-9.601-8.078-4.258-14.577-10.204-19.5-17.797-4.938-7.64-7.407-16.415-7.407-26.25.0-10.32 2.797-19.29 8.422-26.906 5.594-7.625 12.938-13.391 22.032-17.315 9.063-3.946 18.25-6.742 27.562-8.398a157.865 157.865.0 0128.438-2.555c4.47.0 7.936.25 10.405.696.455.219 3.032 2.07 7.735 5.563 4.704 3.462 7.625 5.595 8.75 6.384zm-3.359-100.579c-7.406 8.86-17.734 13.288-30.953 13.288-11.86.0-22.298-4.764-31.266-14.312-9-9.523-15.422-20.328-19.344-32.43-3.937-12.109-5.906-23.984-5.906-35.648.0-13.694 3.596-25.352 10.781-34.976 7.187-9.65 17.5-14.485 30.938-14.485 11.875.0 22.374 5.038 31.437 15.157 9.094 10.085 15.61 21.413 19.517 33.968 3.922 12.54 5.873 24.53 5.873 35.984.0 13.446-3.702 24.61-11.076 33.454z"/></svg></a>
<a class="pr-2 transition-transform hover:scale-125 hover:text-primary-700 dark:hover:text-primary-400" style=will-change:transform href=https://orcid.org/0000-0003-2117-9145 target=_blank rel=noopener rel="me noopener noreferrer" aria-label=Academicons/Orcid><svg style="height:1em" viewBox="0 0 512 512"><path fill="currentcolor" d="M336.62 194.538c-7.13-3.328-13.866-5.56-20.253-6.614-6.365-1.095-16.574-1.612-30.71-1.612h-36.704v152.747h37.634c14.673.0 26.081-1.013 34.224-3.017 8.142-2.004 14.921-4.526 20.356-7.626a69.448 69.448.0 0014.942-11.388c14.488-14.714 21.742-33.273 21.742-55.717.0-22.052-7.44-40.052-22.341-53.982-5.498-5.166-11.822-9.444-18.89-12.793zM256 8C119.022 8 8 119.042 8 256s111.022 248 248 248 248-111.042 248-248S392.978 8 256 8zm-82.336 357.513h-29.389V160.148h29.389zM158.95 138.696c-11.14.0-20.213-9.01-20.213-20.212.0-11.118 9.052-20.191 20.213-20.191 11.18.0 20.232 9.052 20.232 20.191a20.194 20.194.0 01-20.232 20.212zm241.386 163.597c-5.29 12.545-12.834 23.581-22.65 33.088-9.982 9.837-21.597 17.194-34.844 22.196-7.75 3.017-14.839 5.063-21.307 6.117-6.49 1.013-18.828 1.509-37.076 1.509h-64.956V160.148h69.233c27.962.0 50.034 4.154 66.32 12.545 16.265 8.37 29.181 20.728 38.792 36.972 9.61 16.265 14.425 34.018 14.425 53.196.023 13.765-2.666 26.908-7.936 39.432z"/></svg></a></div></div></div></div><div class="pt-1 no-prose w-full"><hr class="border-dotted border-neutral-300 dark:border-neutral-600"><div class="flex flex-col md:flex-row flex-nowrap justify-between gap-5 pt-2"><div><a class="group flex no-underline" href=/post/signifiacion/><span class="mt-[-0.3rem] me-2 text-neutral-700 transition-transform group-hover:-translate-x-[2px] group-hover:text-primary-600 dark:text-neutral dark:group-hover:text-primary-400"><span class="ltr:inline rtl:hidden">&larr;</span></span>
<span class="flex flex-col"><span class="mt-[0.1rem] leading-6 group-hover:underline group-hover:decoration-primary-500">Significaci√≥n Estad√≠stica, ¬øCiencia o Pirotecnia?</span>
<span class="mt-[0.1rem] text-xs text-neutral-500 dark:text-neutral-400">ago. 10, 2025</span></span></a></div><div><a class="group flex text-right no-underline" href=/post/ia/><span class="flex flex-col"><span class="mt-[0.1rem] leading-6 group-hover:underline group-hover:decoration-primary-500">Una Inmersi√≥n Intuitiva en la Arquitectura de los LLMs</span>
<span class="mt-[0.1rem] text-xs text-neutral-500 dark:text-neutral-400">abr. 6, 2025
</span></span><span class="mt-[-0.3rem] ms-2 text-neutral-700 transition-transform group-hover:-translate-x-[2px] group-hover:text-primary-600 dark:text-neutral dark:group-hover:text-primary-400"><span class=ltr:inline>&rarr;</span></span></a></div></div></div><section id=comments><script src=https://giscus.app/client.js data-repo=maicel1978/mi-sitio-personal data-repo-id=R_kgDON3SOug data-category=Announcements data-category-id=DIC_kwDON3SOus4CrXLh data-mapping=pathname data-strict=0 data-reactions-enabled=1 data-emit-metadata=0 data-input-position=top data-theme=preferred_color_scheme data-lang=en data-loading=lazy crossorigin=anonymous async></script></section></div></div></main></article></div></div><div class=page-footer><footer class="container mx-auto flex flex-col justify-items-center text-sm leading-6 mt-24 mb-4 text-slate-700 dark:text-slate-200"><p class=text-center><a href=/privacy/>Pol√≠tica de Privacidad y Confidencialidad Profesional</a></p><p class="powered-by text-center">¬© 2026 Me. This work is licensed under <a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank>CC BY NC ND 4.0</a></p><p class="powered-by footer-license-icons"><a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank aria-label="Creative Commons"><i class="fab fa-creative-commons fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-by fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nc fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nd fa-2x" aria-hidden=true></i></a></p><p class="powered-by text-center">Made with <a href="https://hugoblox.com/?utm_campaign=poweredby" target=_blank rel=noopener>Hugo Blox Builder</a>.</p></footer></div></body></html>